Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) Upgraded at Jefferies Financial Group

Jefferies Financial Group upgraded shares of Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) from a hold rating to a strong-buy rating in a research note published on Tuesday morning,Zacks.com reports.

Other equities research analysts have also recently issued research reports about the company. The Goldman Sachs Group upgraded Shionogi & Co., Ltd. Unsponsored ADR from a “hold” rating to a “strong-buy” rating in a report on Monday, June 15th. Zacks Research raised Shionogi & Co., Ltd. Unsponsored ADR from a “strong sell” rating to a “hold” rating in a report on Monday, May 25th. Two analysts have rated the stock with a Strong Buy rating and one has issued a Hold rating to the company’s stock. According to MarketBeat.com, Shionogi & Co., Ltd. Unsponsored ADR currently has a consensus rating of “Buy”.

Shionogi & Co., Ltd. Unsponsored ADR Stock Up 0.3%

Shionogi & Co., Ltd. Unsponsored ADR stock opened at $8.73 on Tuesday. The stock has a market cap of $14.86 billion, a PE ratio of 10.91, a P/E/G ratio of 3.38 and a beta of 0.09. The company has a debt-to-equity ratio of 0.01, a current ratio of 1.58 and a quick ratio of 1.46. The stock’s fifty day moving average is $8.96 and its two-hundred day moving average is $9.90. Shionogi & Co., Ltd. Unsponsored ADR has a 1-year low of $7.65 and a 1-year high of $12.00.

Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) last issued its quarterly earnings data on Tuesday, May 12th. The company reported $0.18 earnings per share for the quarter, topping the consensus estimate of $0.15 by $0.03. The business had revenue of $881.71 million during the quarter, compared to the consensus estimate of $895.52 million. Shionogi & Co., Ltd. Unsponsored ADR had a net margin of 41.08% and a return on equity of 13.56%. On average, sell-side analysts expect that Shionogi & Co., Ltd. Unsponsored ADR will post 0.8 EPS for the current fiscal year.

Shionogi & Co., Ltd. Unsponsored ADR Company Profile

Shionogi & Co, Ltd. is a Japan-based pharmaceutical company that conducts research, development, manufacturing and marketing of prescription drugs and vaccines. Established in the late 19th century, the company has expanded its focus beyond domestic markets to become a global player in pharmaceuticals, with particular expertise in anti-infectives, pain management, cardiovascular and central nervous system disorders.

The company’s product portfolio spans both established and innovative therapies.